The American journal of managed care
-
Randomized Controlled Trial Multicenter Study Comparative Study Clinical Trial
High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial.
Angiotensin-converting enzyme (ACE) inhibitors reduce heart failure death and hospitalization. Prescribed doses often are lower than randomized clinical trial (RCT) targets and practice guideline recommendations. ⋯ Cost savings from fewer heart failure hospitalizations offset higher ACE inhibitor costs in the high-dose group. The improved clinical outcomes were achieved without increased treatment costs.
-
Randomized Controlled Trial Clinical Trial
A randomized trial of nurse specialist home care for women with high-risk pregnancies: outcomes and costs.
To examine prenatal, maternal, and infant outcomes and costs through 1 year after delivery using a model of prenatal care for women at high risk of delivering low-birth-weight infants in which half of the prenatal care was provided in women's homes by nurse specialists with master's degrees. ⋯ This model of care provides a reasoned solution to improving pregnancy and infant outcomes while reducing healthcare costs.
-
Randomized Controlled Trial Comparative Study Clinical Trial
Effect of rofecoxib therapy on measures of health-related quality of life in patients with osteoarthritis.
Bodily pain and physical disability can negatively impact health-related quality of life (HRQL) in patients with osteoarthritis (OA). ⋯ Rofecoxib treatment increased physical and mental HRQL domain scores on the SF-36. Improvements in mental health with rofecoxib use primarily resulted from effective treatment of OA (i.e., reduction in pain and improvement in physical function).
-
Randomized Controlled Trial Comparative Study Clinical Trial
The impact of schizophrenic patient functionality on service utilization and cost. Based on a presentation by Sandra L. Tunis, PhD.
With the advent of atypical agents in the treatment of schizophrenia, physicians and policy makers must consider the costs that may accompany greater clinical efficacy. Analyses reveal that olanzapine shows a greater clinical cost effectiveness, as well as a greater functional cost effectiveness, than haloperidol, and that functional outcomes, in particular, show promise as important measures of effectiveness. ⋯ When comparing olanzapine with haloperidol, cost savings are seen throughout the treatment period (1 year), with physical functioning most highly affected over time. Functional outcomes can therefore serve 2 purposes: to enhance compliance by improving health-related quality of life and to assist in making both treatment and formulary decisions.